Wednesday | 23rd September, 2020

Wednesday | 23rd September, 2020

New Delhi: On the lines of the World Health Organization (WHO) and the US Food and Drug Administration (US FDA), the Drugs Controller General of India (DCGI) has issued a new set of guidelines for Covid-19 vaccine candidates, focussing on safety, immunogenicity and efficacy parameters. According to the guideline, a Covid-19 vaccine candidate should have at least 50 per cent of efficacy in the Phase-3 clinical trial for it to be widely deployed. Additionally, the pharma companies developing the vaccines must provide adequate data informing the potential risk of vaccine-associated Enhanced Respiratory Disease (ERD).